Chronic lymphocytic leukemia is the most common chronic lymphoproliferative disorder in Spain. The clinical management of this entity varies widely. Currently, in Spain, there are no national consensus guidelines, such as those published in other countries, to guide the diagnosis and treatment of this malignancy and the use of prognostic scores. This article reviews the current scientific literature and addresses issues on the diagnosis of chronic lymphocytic leukemia, the spread of the disease, the presence of comorbidities, the classification of prognostic scores, the common treatment regimens stratified by risk factors, and the management of complications associated with both the disease and its treatment, as well as the various controversies related to this entity. This document was drafted with the collaboration of national experts and aims to establish practical guidelines with their corresponding levels of evidence and grades of recommendation to guide the diagnosis, treatment and follow-up of patients with chronic lymphocytic leukemia.
Keywords: Bendamustina; Bendamustine; Chlorambucil; Chronic lymphocytic leukemia; Chronic lymphoproliferative disorder; Clorambucilo; Fludarabina; Fludarabine; Leucemia linfocítica crónica; Rituximab; Síndrome linfoproliferativo crónico.
Copyright © 2013 Elsevier España, S.L. All rights reserved.